Clinical Trial Update: Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of rosiglitazone extended-release for Alzheimer's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosiglitazone Extended Release Tablets (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED